When was Forge Biologics founded?

Forge Biologics was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Forge Biologics located?

Forge Biologics is headquartered in Columbus, United States. It is registered at Grove City, Ohio.

Who is the current CEO of Forge Biologics?

Timothy Miller of Forge Biologics. They have also founded 1 company.

How many employees does Forge Biologics have?

As of Sep 30, 2026, the latest employee count at Forge Biologics is 439.

Is Forge Biologics a funded company?

Forge Biologics is a funded company, having raised a total of $330M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 21, 2020.

When was the latest funding round of Forge Biologics?

Forge Biologics' latest funding was a $***** Series C round on Sep 12, 2022, with participation from 2 investors.

Where does Forge Biologics rank among its competitors?

Forge Biologics ranks 4th amongst 583 active competitors, of which 211 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was X4 Pharmaceuticals, which secured $85M in Aug, 2025.

Who are the top competitors of Forge Biologics?

Forge Biologics' top competitors include Alnylam, X4 Pharmaceuticals and Spark Therapeutics. Among them, X4 Pharmaceuticals secured the most recent funding round in August, 2025.

Forge Biologics - 2026 Company Profile, Team, Funding & Competitors

Q: Is Forge Biologics an acquired company?

Forge Biologics got acquired by Ajinomoto on Nov 13, 2023.

Forge Biologics is an acquired company based in Columbus (United States), founded in 2020 by Timothy Miller, Erandi De Silva and Jaysson Eicholtz. It operates as a Developer of gene therapeutic solutions for treating multiple diseases. Forge Biologics has raised $330M in funding from investors like RA Capital Management, Aisling Capital and Drive Capital. The company has 583 active competitors, including 211 funded and 138 that have exited. Its top competitors include companies like Alnylam, X4 Pharmaceuticals and Spark Therapeutics.

Company Details

Developer of gene therapeutic solutions for treating multiple diseases. It has developed gene therapies that aim to help patients suffering from rare diseases. Products include FBX-101 which helps to treat infantile Krabbe diseases, FBX-201 for rare and monogenic diseases, and FBX-301 for rare & cancer diseases.

Website: www.forgebiologics.com/
Social
Email ID: *****@forgebiologics.com
Part Of
Registered Address: Grove City, Ohio

Key Metrics

Founded Year

2020

Location

Columbus, United States

Stage

Acquired

Total Funding

$330M in 4 rounds

Latest Funding Round

Series C, Sep 12, 2022, $*****

Investors

RA Capital Management & 8 more

Ranked

4^th among 583 active competitors

Employee Count

439 as on Sep 30, 2026

Similar Companies

Alnylam & 710 more

Exit Details

Acquired by Ajinomoto (Nov 13, 2023)

View Forge Biologics' full profile

Forge Biologics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Forge Biologics, Inc. CIN: 84-3555353 , United States, Active	Dec 31, 2019	-	118 (As on Dec 31, 2021)	-
FORGE BIOLOGICS INC CIN: 843555353 , United States, Active	Dec 31, 1999	-	325 (As on Dec 31, 2024)	-

Forge Biologics got acquired by Ajinomoto on Nov 13, 2023 at an acquisition amount of $*****.

Click here to take a look at Forge Biologics's acquisition in detail

Forge Biologics has raised a total funding of $330M over 4 rounds. Its first funding round was on Jul 21, 2020. Its latest funding round was a Series C round on Sep 12, 2022 for $*****. 2 investors participated in its latest round. Forge Biologics has 9 institutional investors.

Here is the list of recent funding rounds of Forge Biologics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 12, 2022	9409515	Series C	6860214	7571843	2000571	7449575
Jan 10, 2022	2287614	Conventional Debt	9685573	7958546	9103110	MidCap Financial
Apr 28, 2021	5002539	Series B	3423773	8618957	RA Capital Management	Perceptive Advisors & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Forge Biologics's funding rounds and investors

The founders of Forge Biologics are Timothy Miller, Erandi De Silva and Jaysson Eicholtz. Timothy Miller is the CEO of Forge Biologics.

Here are the details of Forge Biologics' key team members:

Timothy Miller: Co-Founder & CEO of Forge Biologics. They serve on the board of 1 company.
Contact Info: 1 email address
Erandi De Silva: Former Co-Founder of Forge Biologics.
Jaysson Eicholtz: Co-Founder of Forge Biologics.
Contact Info: 1 email address

View details of Forge Biologics's Founder profiles and Board Members

Forge Biologics' employee count trend

Forge Biologics has 439 employees as of Sep 26. Here is Forge Biologics's employee count trend over the years:

Employee count trend for Forge Biologics

Uncover Forge Biologics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Forge Biologics include Alnylam, X4 Pharmaceuticals and Spark Therapeutics. Here is the list of Top 10 competitors of Forge Biologics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
2nd	X4 Pharmaceuticals 2014, Boston (United States), Public	Developer of small molecule drugs for the treatment of cancer	$58.2M	Coastlands Capital, Bain Capital Life Sciences ... & 21 others	75/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Perceptive Advisors, Marshall Wace & 7 others	72/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100